iOnctura, headquartered in Geneva, Switzerland, was founded in June 2017 as a spin out from Merck KGaA, funded by Merck Ventures. It is a late stage preclinical biotechnology company developing a pipeline of next generation, best-in-class molecules for the treatment of cancer and fibrosis.
iOnctura is developing a pipeline of carefully selected assets. Programs in oncology aim to harness both immune-mediated and direct anti-tumour activity to deliver superior clinical efficacy in monotherapy or combinations. By building on complementary mechanisms between cancer and fibrosis iOnctura further aims to address high unmet need in fibrotic disease.